Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents

Lanshan Huang,Guillermo Garcia-Manero,Jeffrey L Jorgensen,Sa A Wang,L Jeffrey Medeiros,Maitrayee Goswami,Mark J Routbort,Elias Jabbour

doi:10.1136/jclinpath-2016-203715

Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents

Lanshan Huang, Guillermo Garcia-Manero + Show 6 more

https://doi.org/10.1136/jclinpath-2016-203715

Copy DOI

Journal: Journal of Clinical Pathology	Publication Date: Apr 15, 2016
Citations: 9

Affiliation: The University of Texas MD Anderson Cancer Center, First Affiliated Hospital of GuangXi Medical University, Guangxi Medical University

#Myelodysplastic Syndromes ) And Myelodysplastic/myeloproliferative Neoplasms #Flow Cytometry Immunophenotyping + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

AimsHypomethylating agents (HMAs) exhibit clinical efficacy in patients with myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN). This study was performed to assess residual disease status by flow cytometry immunophenotyping (FCI)...

Full Text